Jerome Kerzerho is the director R&D of Vaxeal. Jérôme is an immunologist with a strong expertise in immuno-oncology and pre-clinical development of advanced immunotherapies from early target validation through to the initiation of clinical trials. Previously, as project leader at the Center for Infectious Diseases and Virology of the University of Southern California (USC - USA), he was head of a multidisciplinary team working on the identification of biomarkers linked to HIV and HCV progression in children and women. Before that, as Postdoctoral Research Associate in the department of Molecular Microbiology and Immunology of USC, Jérôme conducted multiple research projects in the fields of inflammatory allergic diseases and asthma. Jérôme holds a PhD degree in immunology and biotechnology from the University Paris IX. During his PhD at the Atomic Energy Commissariat (France), Jérôme mainly focused on the identification of new clinically relevant T-cell epitopes in tumor antigens and prediction of their immunogenicity in human for the design of advanced cancer immunotherapies and for the immunomonitoring of clinical trials.
Vaxeal’s highly experienced executive team has an extensive track record in company management, immunotherapy product development and regulatory compliance. The Board also brings a wealth of diverse corporate and M&A experience.
Vaxeal’s pre-eminent Scientific Advisory Board advises the company in the fields of immunology, immunotherapy, clinical immuno-oncology, infectious diseases and regulatory affairs.